Skip to content

United Therapeutics UTHR Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$274.9M-24.5%$364.3M+7.6%$338.7M+9.4%$309.5M-3.9%$322.2M+6.9%
$22.6M-0.9%$22.8M+4.1%$21.9M+3.8%$21.1M+6.6%$19.8M+0.5%
$33.9M-13.1%$39M-0.3%$39.1M+3.4%$37.8M+18.9%$31.8M+17.8%
$463.3M+33.8%$346.2M-38.4%$562.1M+193%$191.7M-58.4%$461.2M+35.2%
$100.8M-41.7%$172.9M-17.9%$210.5M+238%$62.2M-17.0%$74.9M-13.6%
$743.7M+427%-$227.6M-$299.9M-82.1%-$164.7M
$1.5B$0-100%$1B$0$0
$0$400M+300%$100M0.0%
-$1.48B$0+100%-$956M-381%-$198.6M-112%-$93.8M-25.6%
-$277.4M-$253M+17.5%-$306.8M-251%$202.7M+41.5%
$362.5M+109%$173.3M-50.7%$351.6M+172%$129.5M-66.5%$386.3M+51.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does United Therapeutics generate?
United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
What is United Therapeutics's free cash flow?
After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
Where does United Therapeutics's cash flow data come from?
Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.